Deerfield Management Company L.P. Series C Sells 4,512 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Deerfield Management Company L.P. Series C cut its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 29.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,841 shares of the specialty pharmaceutical company’s stock after selling 4,512 shares during the quarter. Deerfield Management Company L.P. Series C’s holdings in KalVista Pharmaceuticals were worth $128,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of KALV. Campbell & CO Investment Adviser LLC purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth $507,000. Frazier Life Sciences Management L.P. grew its position in KalVista Pharmaceuticals by 11.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after acquiring an additional 383,435 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in KalVista Pharmaceuticals by 101.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock worth $95,000 after acquiring an additional 4,043 shares during the last quarter. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 94.5% during the first quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 8,750 shares during the period. Finally, ClariVest Asset Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the 1st quarter valued at approximately $659,000.

KalVista Pharmaceuticals Stock Performance

KALV opened at $12.34 on Friday. The stock’s 50 day moving average price is $12.47 and its 200-day moving average price is $12.10. KalVista Pharmaceuticals, Inc. has a one year low of $7.21 and a one year high of $16.88. The stock has a market cap of $520.60 million, a price-to-earnings ratio of -3.63 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. As a group, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,352 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the sale, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. The transaction was disclosed in a filing with the SEC, which is available through this link. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the completion of the sale, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Yea sold 7,102 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the transaction, the insider now owns 84,467 shares in the company, valued at approximately $1,014,448.67. The disclosure for this sale can be found here. Insiders have sold 30,804 shares of company stock valued at $372,112 in the last 90 days. Company insiders own 12.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KALV. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.